Medivir
2.8
SEK
+6.06 %
MVIR
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
2 following
+6.06%
+2.56%
0%
-12.23%
-6.35%
-1.75%
+10.84%
-69.65%
-81.12%
-95.22%
www.medivir.com/investors
Medivir is a pharmaceutical company. The company develops drugs and treatments with a focus on cancers and other serious diseases. The company invests in indication areas where available treatment methods are limited or completely lacking research. Collaborations with other partners are part of the business model, and drug development, as well as commercialization, are conducted either in-house or in partnership with other pharmaceutical companies. The head office is located in Huddinge.
Revenue
7.6M
EBIT %
-1,202.63 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
MVIR
Daily low / high price
2.64 / 2.8
SEK
Market cap
320.93M SEK
Turnover
103.02K SEK
Volume
37K
Latest videos
Financial calendar
Annual report
2025-02-18
Interim report
2025-04-29
General meeting
2025-05-07
Interim report
2025-08-21
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Linc AB | 11.2 % | 11.4 % |
Nordea Funds AB | 8.9 % | 9.1 % |
Avanza Pension | 7.1 % | 7.2 % |
Hallberg Management AB | 6.6 % | 6.7 % |
HealthInvest Partners AB | 3.2 % | 3.2 % |
NGL Förvaltning AB | 2.9 % | 2.9 % |
Johan Claesson | 2.4 % | 2.5 % |
Privatperson | 2.1 % | 2.2 % |
CA Fastigheter AB | 2.1 % | 2.1 % |
Nordea Livförsäkring Sverige AB | 1.8 % | 1.9 % |
ShowingAll content types
Medivir's CEO: "There is an obvious need for fostrox"
Penser Access & Future by Carnegie: Medivir: Finansieringsfrågan fortsatt i fokus - Q3 review
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools